Literature DB >> 2303362

Endometrial adenocarcinoma, adjuvant radiotherapy tailored to prognostic factors.

J H Meerwaldt1, C J Hoekstra, W L van Putten, A J Tjokrowardojo, P C Koper.   

Abstract

The optimal adjuvant radiotherapy for surgically treated endometrial cancer has not yet been defined. We report on 389 patients treated between 1970 and 1985 with adjuvant radiotherapy. The treatment was tailored to the known prognostic factors: myometrial invasion and grade of differentiation of the tumor. Ten-year overall survival was 67%, 10-year relapse-free survival 77%; 23% relapse, of which 21% distant and 6% locoregional relapse. In a multivariate analysis, stage (pT), grade, and myometrial invasion were prognostic factors. The number of locoregional failures was very small (n = 23). This small number, the fact that radiation treatment was tailored to prognostic factors, and the absence of a nontreated control group precluded an analysis of the effect of the adjuvant irradiation. Large randomized studies with a control (no treatment) arm should be performed to determine the value of adjuvant radiotherapy.

Entities:  

Mesh:

Year:  1990        PMID: 2303362     DOI: 10.1016/0360-3016(90)90093-y

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Adjuvant radiotherapy for stage I endometrial cancer.

Authors:  Anthony Kong; Nick Johnson; Henry C Kitchener; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

2.  Improving locoregional outcome in high-intermediate-risk and high-risk stage I endometrial cancer with surgical staging followed by brachytherapy.

Authors:  Candan Demiroz Abakay; Sonay Arslan; Meral Kurt; Sibel Cetintas
Journal:  Radiat Oncol J       Date:  2022-05-25

3.  High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome.

Authors:  Gustavo A Viani; Barbara F Patia; Antonio C Pellizzon; Marcel D De Melo; Paulo E Novaes; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.